Stock 6535 LUMOSA THERAPEUTICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Lumosa Therapeutics Co., Ltd.

Equities

6535

TW0006535008

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 23/05/2024 BST 		5-day change 1st Jan Change
184.5 TWD +1.37% Intraday chart for Lumosa Therapeutics Co., Ltd. -0.27% +170.13%
05-14 Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson CI
05-14 Lumosa Therapeutics Co., Ltd. Announces the Change in Juristic-Person Director Representative CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lumosa Therapeutics Co., Ltd. Announces the Change of Chairperson
Lumosa Therapeutics Co., Ltd. Announces the Change in Juristic-Person Director Representative
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke
Lumosa Therapeutics Co., Ltd. Receives Approval to Initiate Phase 2, Multiple-Dose Study of Its LT3001
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Lumosa Therapeutics Co., Ltd. Approves the Exclusive Licensing Agreement with Gufic Biosciences for LT1001, A Long-Acting Analgesic Injection
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Lumosa Therapeutics Co., Ltd. Approves Formulation Patent for Lumosas Lt3001, A New Drug for Acute Ischemic Stroke
Lumosa Therapeutics Co., Ltd. Appoints Hsin-Jung Lin as Member of the Audit Committee
Lumosa Therapeutics Co., Ltd. Announces Appointment of Hsin-Jung Lin as Independent Director
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Lumosa Therapeutics Co., Ltd. Appoints Lanying Huang as Corporate Governance Officer
Lumosa Therapeutics Co., Ltd. Approves Exclusive Licensing Agreement with Pakistan’s AJM Pharma Pvt. Ltd. for LT1001, A Long-Acting Analgesic Injection
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Lumosa Therapeutics Co., Ltd. Approves the Revised Exclusive Licensing Agreement for the Veterinary Analgesic with Skyline Vet Pharma, Inc
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Lumosa Therapeutics Co., Ltd. Approves the Amendments for the Exclusive Licensing Agreement for the Veterinary Analgesic
Lumosa Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
LUMOSA Therapeutics Announces TFDA’s Clearance of Phase 2 IND Application for Multiple-Dose of LT3001 in Patients
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6535 Stock
  4. News Lumosa Therapeutics Co., Ltd.
  5. Other languages